NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/07/2025
Back to search
Official data from USPTO
IAMBIC THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
IAMBIC THERAPEUTICS
ST13
US500000097905484Class
42
Filing
97905484
Registration
7977150
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
10/08/2025
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
04/25/2023
Registration date
10/07/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/07/2025
Last transaction
10/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2023-10-00
First use in commerce
2023-10-00
Drawing code
4
Owner type
03
Owner location
San Diego, CA
Examiner
SOBRAL,CHRISTINA
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
IAMBIC THERAPEUTICS, INC.
IAMBIC THERAPEUTICS, INC.
Entos, Inc.
Representatives
Alyssa M. Worsham WILSON SONSINI GOODRICH & ROSATI
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
research and development in the field of computational biologybioinformaticsgenomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceuticalmedicalscientificbiotechnologybiopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological servicesresearch and design in the field of computational chemistrymachine learning and artificial intelligence for use in chemistrybiologyphysicsbiochemistrychemical engineeringcomputer sciencedesign and optimization of moleculesmaterialsdrugs; chemistry serviceslaboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drugmolecular discovery servicesproduct development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drugmaterialsmolecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistrybiologyphysicsbiochemistrychemical engineeringcomputer sciencethe discovery of new moleculesmaterialsdrugsmachine learning techniques; computer programming in the fields of molecularmaterialsdrug development; computer consultancy services being computer software consultation in the field of drugmaterialsmolecular development; computer software consultation servicesassistance and consulting in connection with the development of computer applicationsdatabases and systems for use in the field of drugmaterialsmolecular development; consulting services in the design and implementation of computer-based information systems for businessprovision of online information relating to computer hardware and software design in the field of drugmaterialsmolecular development; creationmaintenancehostingdesign of websites in the field of drugmaterialsmolecular development; provision of online non-downloadable software for simulations for drugmaterialsmolecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drugmaterialsmolecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drugmaterialsmolecular discovery; creating website based indexes of information for others using information technology for use in the field of drugmaterialsmolecular development; computer graphics design servicesrealization of computer graphics and digital imaging for use in the field of drugmaterialsmolecular development; scientific research in connection with computerized automation of technical processes for use in the field of drugmaterialsmolecular development; software as a services (SAAS) services in the nature of hosting cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering moleculesdrugsbattery materialsother molecular products
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/03/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/16/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/16/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/16/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/16/2025
IUAF
USE AMENDMENT FILED
04/23/2025
EISU
TEAS STATEMENT OF USE RECEIVED
04/23/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/17/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/05/2024
PUBO
PUBLISHED FOR OPPOSITION
11/05/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/16/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/25/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/13/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/13/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/13/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
07/16/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
07/16/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/17/2024
GNRT
NON-FINAL ACTION E-MAILED
04/17/2024
CNRT
NON-FINAL ACTION WRITTEN
04/17/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/01/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/01/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/23/2024
GNRT
NON-FINAL ACTION E-MAILED
01/23/2024
CNRT
NON-FINAL ACTION WRITTEN
01/23/2024
DOCK
ASSIGNED TO EXAMINER
01/23/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/28/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/23/2023
NWAP
NEW APPLICATION ENTERED
04/28/2023
Continuous trademark protection
Get notified about every new filing that threatens IAMBIC THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.